Tilray Brands (TLRY) Return on Capital Employed (2018 - 2026)
Tilray Brands (TLRY) posted Return on Capital Employed of 81.49% for Q1 2026, up 32.9% on a QoQ basis from 121.45% in Q4 2025.
Tilray Brands (TLRY) Return on Capital Employed (2018 - 2026) Analysis & Trends
Tilray Brands' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 81.49% for Q1 2026.
- Quarterly Return on Capital Employed changed N/A year-over-year to 81.49% in Q1 2026, while the trailing twelve-month figure through Feb 2026 was 81.49% (changed N/A YoY) and the FY2025 annual result came in at 79.6%, down 7519.0% from the prior year.
- Return on Capital Employed was 81.49% for Q1 2026 at Tilray Brands, up from 121.45% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 3.93% in Q1 2022 and bottomed at 123.92% in Q3 2025.
- A 5-year average of 35.24% and a median of 11.4% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed soared 3292 bps — and 2025, when it sank 11944 bps.
- Tilray Brands' Return on Capital Employed stood at 10.94% in 2022, then tumbled by 216 bps to 34.57% in 2023, then soared by 87 bps to 4.49% in 2024, then slumped by 2603 bps to 121.45% in 2025, then soared by 33 bps to 81.49% in 2026.
- Business Quant data shows TLRY's Return on Capital Employed at 81.49% in Q1 2026, 121.45% in Q4 2025, and 123.92% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Tilray Brands | 465.02 Mn | 373.06 Mn | 54.95 Mn | -81.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -81.49% |
| Nov 30, 2025 | -121.45% |
| Aug 31, 2025 | -123.92% |
| Nov 30, 2024 | -4.49% |
| Aug 31, 2024 | -4.48% |
| May 31, 2024 | -4.46% |
| Feb 29, 2024 | -6.30% |
| Nov 30, 2023 | -34.57% |
| Aug 31, 2023 | -36.22% |
| May 31, 2023 | -35.04% |
| Feb 28, 2023 | -39.21% |
| Nov 30, 2022 | -10.94% |
| Aug 31, 2022 | -10.71% |
| May 31, 2022 | -11.40% |
| Feb 28, 2022 | -3.93% |
| Nov 30, 2021 | -4.00% |
| Aug 31, 2021 | -3.52% |
| May 31, 2020 | -26.28% |
| Mar 31, 2020 | -41.96% |
| Dec 31, 2019 | -30.30% |